Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Jul / The Natural Drug Factory
Discovery & Development Drug Discovery Research News

The Natural Drug Factory

Exploring how microbe mega-enzymes synthesize critical chemical compounds – and drugs

By Maryam Mahdi 07/28/2020 1 min read Quick Read (pre 2022)

Share

Researchers are shining a new light on how nonribosomal peptide synthetases (NRPS) work (1). Known for their ability to make “natural product peptides” – small, but potent chemical compounds – these multienzyme nanomachines have been used to develop a variety of drugs, including immunosuppressants and antibacterials.

“NRPS act as machines, with many moving parts and reaction centers that all work together,” says Martin Schmeing, Associate Professor in the Department of Biochemistry at McGill University. “They follow an elegant sort of logic in which a subsection called a module facilitates reactions that add building blocks to a growing chemical. The enzyme then passes the (now bigger) chemical to the next module, where the next building block is added, and so on.”

But the configuration of these modules has remained elusive – until now. Using ultra-intense X-ray beams, Schmeing and his colleagues were able to visualize the NRPS’ mechanism of action, by studying an NRPS called depsipeptide synthetase “We found that the modules converted keto acids into building blocks that can be added to peptide drugs,” says Schmeing. “This helps us understand how NRPS use so many building blocks to make different compounds and therapeutics. This understanding will help us build new therapeutics from new combinations of building blocks.” The researchers believe the module subsection unexpectedly acquired portions of another enzyme through evolution, enabling it to use different building blocks in chemical synthesis. 

This knowledge should help us to begin producing more potent drugs with desired properties using NRPS. But Schmeing points out that there is still much to learn before we can fully understand these nanomachines. “In our study, there was a small, but important section of the module that was not visible in some of our experiments,” he says. “We are aiming to visualize this in the future and evaluate its contributions to NRPS function.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. DA Alonzo et al., “Structural basis of keto acid utilization in nonribosomal depsipeptide synthesis”, Nature Chemical Biology, 16, 493 (2020).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.